Progesterone vaginal - Teva

Drug Profile

Progesterone vaginal - Teva

Alternative Names: DR-201; Milprosa

Latest Information Update: 16 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Teva Pharmaceutical Industries
  • Class Hormonal contraceptives; Hormonal replacements; Infertility therapies; Pregnenediones; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Female infertility

Most Recent Events

  • 28 Sep 2015 Progesterone vaginal ring licensed to Ferring Pharmaceuticals worldwide
  • 31 Dec 2014 Discontinued - Preregistration for Female infertility in USA and Israel (Vaginal)
  • 01 Aug 2014 Teva completes a phase I bioequivalence trial in healthy postmenopausal women in USA (NCT02092571)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top